ATE474590T1 - Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen - Google Patents

Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen

Info

Publication number
ATE474590T1
ATE474590T1 AT00927193T AT00927193T ATE474590T1 AT E474590 T1 ATE474590 T1 AT E474590T1 AT 00927193 T AT00927193 T AT 00927193T AT 00927193 T AT00927193 T AT 00927193T AT E474590 T1 ATE474590 T1 AT E474590T1
Authority
AT
Austria
Prior art keywords
recipient
prevention
rejection
treatment
xenografts
Prior art date
Application number
AT00927193T
Other languages
German (de)
English (en)
Inventor
Hendrik Schuurman
Emanuele Cozzi
Francoise Richard
Guy Taccard
David White
Peter Friend
John Wallwork
Paolo Brenner
Original Assignee
Paolo Brenner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9910835.9A external-priority patent/GB9910835D0/en
Priority claimed from GBGB9925443.5A external-priority patent/GB9925443D0/en
Application filed by Paolo Brenner filed Critical Paolo Brenner
Application granted granted Critical
Publication of ATE474590T1 publication Critical patent/ATE474590T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00927193T 1999-05-10 2000-05-10 Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen ATE474590T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9910835.9A GB9910835D0 (en) 1999-05-10 1999-05-10 Organic compounds
GBGB9925443.5A GB9925443D0 (en) 1999-10-27 1999-10-27 Organic compounds
PCT/EP2000/004250 WO2000067773A2 (en) 1999-05-10 2000-05-10 Combinations of immunosupressive agents for the treatment or prevention of graft rejections

Publications (1)

Publication Number Publication Date
ATE474590T1 true ATE474590T1 (de) 2010-08-15

Family

ID=26315533

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00927193T ATE474590T1 (de) 1999-05-10 2000-05-10 Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen

Country Status (7)

Country Link
US (5) US20020132764A1 (https=)
EP (2) EP1980263A1 (https=)
JP (1) JP2002544167A (https=)
AT (1) ATE474590T1 (https=)
AU (1) AU4565000A (https=)
DE (1) DE60044717D1 (https=)
WO (1) WO2000067773A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1208847B8 (en) * 1996-07-30 2007-02-14 Novartis AG Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
EP2298299A3 (en) 2000-01-14 2012-02-29 The Trustees Of The University Of Pennsylvania O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
CN105792775B (zh) 2013-09-24 2019-02-19 吉纳生命科学公司 用于细胞植入物的气体处理的系统
MX2019005676A (es) 2016-11-15 2019-09-10 Giner Life Sciences Inc Dispositivo percutáneo de difusión de gases adecuado para su uso con un implante subcutáneo.
JP7199632B2 (ja) 2017-05-04 2023-01-06 ガイナー，インク． 堅牢なインプラント可能なガス送達装置ならびにそれを含む方法、システムおよび装置

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178858A (en) * 1987-12-02 1993-01-12 Reichert Thomas A Method for prevention of graft versus host disease
US5135934A (en) 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
AU666128B2 (en) 1991-08-23 1996-02-01 Alberta Research Council Inc. Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5843452A (en) * 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
ES2242189T3 (es) 1994-05-13 2005-11-01 Miltenyi Biotec Gmbh Columna esteril y apirogena copulada a una proteina con miras a la fijacion y extraccion de sustancias dadas de la sangre.
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
PE52896A1 (es) 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
US5697109A (en) 1994-10-28 1997-12-16 Barton Medical Corporation Patient transport system
US5631282A (en) * 1995-06-07 1997-05-20 Merck & Co., Inc. Triterpenes
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
EP1208847B8 (en) * 1996-07-30 2007-02-14 Novartis AG Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
GB9619706D0 (en) 1996-09-20 1996-11-06 Pharmacia Spa Synergistic immunosuppressant composition containing a 2,2'-bi-1H-pyrrole comp und
US5962415A (en) * 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
CA2284729A1 (en) 1997-04-18 1998-10-29 Novartis Ag Neoglycoproteins
AU7935598A (en) 1997-07-14 1999-02-10 Nippon Meat Packers, Inc. Transgenic mammals

Also Published As

Publication number Publication date
JP2002544167A (ja) 2002-12-24
WO2000067773A2 (en) 2000-11-16
US20050277585A1 (en) 2005-12-15
US8435520B2 (en) 2013-05-07
EP1181034A2 (en) 2002-02-27
US20110142953A1 (en) 2011-06-16
WO2000067773A3 (en) 2001-06-28
US20020132764A1 (en) 2002-09-19
AU4565000A (en) 2000-11-21
US20080199478A1 (en) 2008-08-21
DE60044717D1 (de) 2010-09-02
EP1181034B1 (en) 2010-07-21
US20070060511A1 (en) 2007-03-15
EP1980263A1 (en) 2008-10-15

Similar Documents

Publication Publication Date Title
ATE319312T1 (de) Suppressorzellen zur prävention und behandlung von immunantworten bei transplantationen
ATE269354T1 (de) Depsipeptide und deren analoge zur verwendung als immunosuppressiva
ATE340586T1 (de) Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
MXPA03006557A (es) METODO Y APARATO PARA REMOVER SUSTANCIAS DE LOS VASOS DEL CORAZON Y OTRAS PARTES DEL CUERPO, PARA MINIMIZAR O EVITAR DAnOS O DISFUNCIONES RENALES U OTROS.
ATE350019T1 (de) Verfahren zur behandlung von kapseln und trockenen gepulverten pharmazeutischen formulierungen
DE602004012816D1 (de) Selbstexpandierbarer Stent und Stenteinbringungssystem zur Behandlung von Gefässerkrankungen
ATE424893T1 (de) Behandlung und vorbeugung von insulin- produzierende zelltransplantatabstossung
MXPA03008820A (es) Compuestos generadores de monoxido de carbono, para el tratamiento de desordenes vasculares, inflamatorios e inmunologicos.
ATE198706T1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
ATE474590T1 (de) Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
DE69423533D1 (de) Zubereitungen zur Behandlung von Impotenz, die ein Alpha-1 inhibitor und ein Alpha-2 inhibitor enthalten
ATE275117T1 (de) Behandlung von abfällen
DE60020727D1 (de) Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
ATE290393T1 (de) Milchsäurebakterien zur behandlung und prophylaxe von giardiasis
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE250936T1 (de) Verfahren zur behandlung von erkrankungen oder störungen des innenohrs
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
ATE294582T1 (de) Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs
DE602005016729D1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
EP0949209A3 (en) Biological process and anoxic and/or aerobic biological reactor for the purification of liquid residues
RU98109220A (ru) Способ лечения экземы
IT1283589B1 (it) Procedimento per il trattamento di rifiuti solidi urbani e assimilati, nonche' impianto per la realizzazione del procedimento
RU2002120789A (ru) Способ лечения инфекции синтетического сосудистого протеза
AU2003254039A8 (en) Method for removing pyrogens from plasma and blood for treatment of septic shock
ATE340584T1 (de) Zusammensetzung und verfahren zur behandlung chronischer allograft-abstossung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1181034

Country of ref document: EP